Vancouver, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, today provided the following update regarding how it expects to overcome potential challenges of recruiting patients for human trials.
View post:
BetterLife Provides Important Update on its Australian Clinical Study Design
Recommendation and review posted by Fredricko
